Shaanxi Coal Industry Co Ltd

Shaanxi Coal Industry released its 2026 interim report. Total operating revenue was 78.895 billion yuan, up 1.17% year on year, and net profit attributable to the parent company was 11.272 billion yuan, up 47.57% year on year. Net cash inflow from operating activities was 20.537 billion yuan, up 29.86% year on year. The company's asset-liability ratio was 40.26%, down 2.61 percentage points year on year. Gross margin was 33.36%, rising for four consecutive quarters. ROE was 11.15%, up 2.56 percentage points year on year. Diluted earnings per share were 1.16 yuan, up 46.84% year on year.

Shaanxi Coal Industry released its 2026 semi-annual report, achieving operating revenue of 78.895 billion yuan, up 1.17% year on year; net profit attributable to shareholders of the listed company was 11.272 billion yuan, up 47.57% year on year. The profit growth was mainly due to year-on-year increases in the selling price and sales volume of self-produced coal. The company plans to distribute a cash dividend of 0.58 yuan per 10 shares, tax included. Second-quarter net profit was 7.062 billion yuan, up 67% quarter on quarter, within the previously guided range of 7.019 billion to 7.477 billion yuan.

China's A-share market saw mixed performance on July 6, with the Shanghai Composite Index edging down 0.06 percent to 4,041.24 points and the ChiNext Index falling 1.77 percent. Combined turnover on the two exchanges reached approximately 3.11 trillion yuan. The coal sector rallied in the afternoon, with Haohua Energy hitting its daily limit at the close, Xinji Energy surging nearly 9 percent, and Shaanxi Coal Industry climbing over 7 percent. The pharmaceutical sector was strong, with innovative drug concepts standing out. Shouyao Holdings briefly surged by the 20 percent daily limit, and Gan & Lee Pharmaceuticals hit its daily limit. The PCB concept slumped sharply, with Sinoma Science & Technology, China Jushi, and Haohua Science & Technology all hitting their daily limit down. Reports indicate that Nvidia's next-generation Kyber NVL144 rack architecture may face delivery delays of more than 12 months due to manufacturing process challenges with PCB mid-boards, pushing mass production back to 2028.